Want to see CANF full AI Analyst Report?
CANF Stock Chart & Stats
$3.32
-$0.04(-1.25%)
At close: 4:00 PM EDT
$3.32
-$0.04(-1.25%)
Day’s Range― - ―
52-Week Range$1.75 - $12.30
Previous Close$3.26
Volume20.73K
Average Volume (3M)50.34K
Market Cap
$5.91M
Enterprise Value-$1.48M
Total Cash (Recent Filing)$7.04M
Total Debt (Recent Filing)$49.00K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Apr 01, 2027EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding3,031,547
10 Day Avg. Volume31,707
30 Day Avg. Volume50,339
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)88.41
Price to Sales (P/S)1211.03
P/FCF Ratio-54.79
Enterprise Value/Market Cap-0.25
Enterprise Value/Revenue-3.66
Enterprise Value/Gross Profit-3.66
Enterprise Value/Ebitda0.15
Forecast
1Y Price Target
$8.00Price Target Upside140.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.68
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Pipeline And Regulatory SupportTwo lead candidates have reached Phase III development, while namodenoson benefits from Fast Track and orphan-drug designations. These regulatory pathways may streamline interactions and clarify potential approval routes, strengthening the pipeline’s strategic value if pivotal trials succeed.
Clinical Evidence In Advanced Liver DiseaseThe peer-reviewed case provides clinically relevant evidence that namodenoson may help manage severe complications of decompensated cirrhosis. Although a single case is not conclusive, the reported durability and transplant bridge support continued development in a high-need liver-care setting.
Expansion Into Pancreatic CancerNamodenoson has generated a safety signal and durable disease stabilization in heavily pretreated pancreatic cancer patients, supporting expansion into a difficult-to-treat indication. A planned combination trial could broaden the candidate’s development opportunity if follow-on efficacy is confirmed.
Bears Say
Minimal Revenue And Severe LossesThe company has not yet established meaningful operating scale: revenue remains minimal while operating expenses produce losses vastly larger than sales. This weak earnings base limits internal funding capacity and makes future financial performance highly dependent on successful clinical development.
Persistent Cash BurnPersistent negative operating and free cash flow show that the business is consuming cash rather than funding development internally. Continued investment in trials therefore requires external capital or partnering proceeds, leaving execution exposed to financing needs over the coming quarters.
Financing-related Dilution RiskThe warrant inducement raised near-term funding for research and clinical trials, but the accompanying warrants create a substantial potential increase in ADS count. Repeated reliance on such structured financing can dilute existing holders and reflects ongoing dependence on external capital.
Can-Fite BioPharma News
CANF FAQ
What was Can-Fite BioPharma’s price range in the past 12 months?
Can-Fite BioPharma lowest stock price was $1.75 and its highest was $12.30 in the past 12 months.
What is Can-Fite BioPharma’s market cap?
Can-Fite BioPharma’s market cap is $5.91M.
When is Can-Fite BioPharma’s upcoming earnings report date?
Can-Fite BioPharma’s upcoming earnings report date is Apr 01, 2027 which is in 163 days.
How were Can-Fite BioPharma’s earnings last quarter?
Can-Fite BioPharma released its earnings results on Sep 08, 2026. The company reported -$1.24 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.91.
Is Can-Fite BioPharma overvalued?
According to Wall Street analysts Can-Fite BioPharma’s price is currently Undervalued.
Does Can-Fite BioPharma pay dividends?
Can-Fite BioPharma does not currently pay dividends.
What is Can-Fite BioPharma’s EPS estimate?
Can-Fite BioPharma’s EPS estimate is -0.8.
How many shares outstanding does Can-Fite BioPharma have?
Can-Fite BioPharma has 3,031,547 shares outstanding.
What happened to Can-Fite BioPharma’s price movement after its last earnings report?
Can-Fite BioPharma reported an EPS of -$1.24 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went up 2.691%.
Which hedge fund is a major shareholder of Can-Fite BioPharma?
Currently, no hedge funds are holding shares in CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
CANF Stock 12 Month Forecast
Average Price Target
$8.00
▲(140.96% Upside)